<DOC>
	<DOCNO>NCT00527735</DOCNO>
	<brief_summary>The purpose study determine whether ipilimumab give paclitaxel/carboplatin clinical benefit compare paclitaxel/carboplatin alone patient previously untreated lung cancer .</brief_summary>
	<brief_title>Phase II Study Previously Untreated Subjects With Non Small Cell Lung Cancer ( NSCLC ) Small Cell Lung Cancer ( SCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm lung cancer ( Stage IIIb/IV nonsmallcell lung cancer extensive stage smallcell lung cancer [ SCLC ] ) Measurable tumor lesion ( long locate previously irradiate area ) define modified World Health Organization criterion Eastern Cooperative Oncology Group performance status ≤1 study entry Accessible treatment followup Brain metastases Malignant pleural effusion Autoimmune disease Motor neuropathy autoimmune origin SCLCrelated paraneoplastic syndrome Any concurrent malignancy nonmelanoma skin cancer ; carcinoma situ cervix breast ; prostate cancer treat systemic therapy ( participant previous malignancy without evidence disease 5 year allow enter study ) Prior systemic therapy lung cancer . Prior radiation therapy locoregional surgery perform later least 3 week prior randomization date allow . Grade 2 peripheral neuropathy ( motor sensory ) Known HIV hepatitis B C infection Chronic use immunosuppressant and/or systemic corticosteroid ( used management cancer noncancerrelated illness ) . However , use corticosteroid allow used premedication paclitaxel infusion treat immunerelated adverse event adrenal insufficiency . Inadequate hematologic function define absolute neutrophil count &lt; 1,500/mm^3 , platelet count &lt; 100,000/mm^3 , hemoglobin level &lt; 9 g/dL . Inadequate hepatic function define total bilirubin level &gt; 2.0 time upper limit normal ( ULN ) , ≥2.5 time ULN liver metastasis present , aspartate aminotransferase alanine aminotransferase level ≥2.5 time ULN ≥5 time ULN liver metastases present . Inadequate renal function define serum creatinine level ≥2.5 time ULN Inadequate creatinine clearance define less 50 mL/min .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Non Small Cell Lung Cancer ( NSCLC )</keyword>
	<keyword>Small Cell Lung Cancer ( SCLC )</keyword>
</DOC>